A Long-term Follow-up Study in Participants Who Received CTX001
A Long-term Follow-up Study in Participants Who Received CTX001
Enrolling by invitation · NCT04208529 · Registry updated 2026-08-11Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Long-term Follow-up Study in Participants Who Received CTX001 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, anemia, beta thalassemia, familial hemolytic anemia, hematologic disorder, hemolytic anemia, hereditary disease, inherited hemoglobinopathy, sickle cell disease, thalassemia | Enrolling by invitation | Phase 3 | 2026-08-11 | NCT04208529 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| CRISPR Therapeutics | 6 |
| Vertex Pharmaceuticals Incorporated | 37 |
20 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.